RecruitingPhase 2NCT07501702
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis
Sponsor
Vertex Pharmaceuticals Incorporated
Enrollment
30 participants
Start Date
Apr 16, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria2
- Age 18-80 years
- Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV
Exclusion Criteria2
- History of thymic surgery within 6 months of screening
- History of malignancy within the last 5 years
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPovetacicept
Solution for Subcutaneous Injection.
DRUGPlacebo
Solution for Subcutaneous Injection.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07501702
Related Trials
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
NCT0690925314 locations
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
NCT070729881 location
Markers of Favorable Response to Complement Inhibitors Therapy
NCT064557091 location
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
NCT058688371 location
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT050673486 locations